The researchers in the recently reported BOLERO-2 and TAMRAD translational studies of ER + metastatic BC patients [39,40] found that all patients derived benefit from the addition of everolimus to exemestane or tamoxifen, respectively, regardless of their PIK3CA genotype. The gene discussed is ESR1; the disease is breast cancer.